Active Ingredients: Gabapentin
The results of this study were not published.
However, treatment had to be discontinued due to recurrent symptomatic hyponatraemia. Several drugs, including topiramate, gabapentin, and amitriptyline, failed to improve the trigeminal neuralgia. ESL at low doses 400 mg daily achieved excellent pain control without altering the plasma sodium concentration.
Cuadrado et al. Symptoms reappeared when the dose was reduced. The clinical case presented by Aledo Serrano et al.
The patient responded partially to CBZ but experienced severe adverse reactions. The patient remained asymptomatic with ESL dosed at 1200 mg daily. The main variables were pain intensity before and after treatment VAS, frequency of pain attacks before and after treatment, and adverse reactions.
The study included 10 patients 4 in monotherapy; 7 were women, and mean age was 67. Mean follow-up time was 24. No patient experienced severe adverse reactions; one presented hyponatraemia.
Pain intensity and frequency decreased in 9 of the 10 patients.
In these patients, pain intensity decreased from 8. Response to ESL was evaluated in 15 patients over a 6-month period; the initial evaluation included the data from the clinical history, physical examination, complementary tests, information about previous treatments, and the adverse reactions motivating drug discontinuation.
Patients were subsequently evaluated at 3 and 6 months to assess treatment efficacy and any adverse reactions. Eslicarbazepine acetate in series of cases of different aetiologies At the SEN's 63 rd Annual Meeting, Barcelona, Tena Mora 26 presented in poster format the results of a prospective, descriptive study of the efficacy and safety of ESL in monotherapy in 6 patients with different types of neuropathic pain.
Analyses complete blood count, coagulation test, sodium and potassium levels, kidney and liver function were performed at 1 and 3 months after treatment onset; the VAS was completed during the first consultation VAS 1, at 1 month VAS 2, and at 3 months of follow-up VAS 3.
None of the patients showed alterations in blood analysis results during the study period 3 months. According to a recent study by Soares-da-Silva another at the 10,11 position.